PHARMACOKINETICS OF NEUROLEPTICS
- ADMINISTRATION: per os
- ½♥: 20-40 hrs
- PLASMA PROTEIN BINDIGN: 70%
- REACHES CNS: 30 MINS/ 1 HRS (HIGH LIPOSOLUBIILTY)
- HEPATIC METABOLISM: CYP2D6
PHARMACODYNAMIC OF NEUROLEPTICS
Neuroleptics block D2 receptors in the mesolimbic system, so they are effective on positive symptoms, and not on negative and cognitive symptoms.
- Block D2 receptors in the nigrostriatal system (NSc) (With extrapyramidal side effects and tardive diskinesias).
- Block D2 receptors in the tuber-infundibular system (Hyperprolactinemia with sexual disfunctions and osteoporosis).
- Block D2 receptors in the mesocortical system (Inducing or worsening negative symptoms).
- Block α1 receptors (Causing dizziness sedation and orthostatic hypotension).
- Block M receptors (Causing loss of memory, xerostomy, blurred vision, constipation and urinary retention).
- Block H1 receptors (Causing sedation and weight gain).
